Introduction
============

Elevated lead exposure in early life is associated with growth retardation, neurotoxicity, impaired cognitive development in infancy, and deficits in attention and executive function ([@r4], [@r5]). Accumulating evidence also indicates that the effect of lead exposure in early childhood can change neurochemistry ([@r7]), cause neurobehavioral and cognitive deficits in later life ([@r28]; [@r56]; [@r68]; [@r72]), decrease brain volume, and increase the rate of criminal arrest in adulthood ([@r9]; [@r70]). Although the current actionable concentration for lead is 5 μg/dL in the United States, the threshold for its toxicity is unknown. Furthermore, the mechanisms by which lead exposure affects diverse neuropathological outcomes is not clearly defined, although epigenetic mechanisms have been proposed ([@r71]).

Environmental exposures to both physical and chemical agents, especially during early development, can induce alterations in DNA methylation that alter disease susceptibility in adulthood ([@r6]; [@r21], [@r20]; [@r65]). Animal studies likewise suggest that epigenetic modifications may link lead exposure to neurotoxicity and attention deficit disorders ([@r25]; [@r42]), but stable epigenetic targets responsive to early lead exposure in humans remain uncharacterized.

Because of the relative ease of measuring genomic DNA cytosine methylation at CpG dinucleotides, this end point is the most commonly investigated epigenetic modification in epidemiologic studies. *In vitro* and *in vivo* studies demonstrate that DNA methylation is altered by exposure to toxic metals, including arsenic, cadmium, and lead ([@r8]; [@r52]; [@r62]). The only epigenetic studies conducted in humans thus far have evaluated DNA methylation at *Alu* and *LINE* repeat elements. They showed associations between maternal patella lead levels and global DNA hypomethylation in newborns ([@r49]) and adult males ([@r71]). Although the biological significance of reduced DNA methylation at repetitive elements in lead-exposed humans is unknown, this epigenetic change also occurs frequently in cancer, where it is believed to result in chromosomal instability and genomic mutations ([@r67]).

Imprinted genes are characterized by parent-of-origin--dependent monoallelic expression, with the functionally haploid state controlled by differentially methylated regions (DMRs). The inherited imprint methylation marks at these DMRs are established during gametogenesis (i.e., gametic imprints) or early in embryogenesis (i.e., somatic imprints) ([@r3]; [@r53]). Epigenetic dysregulation of imprinted genes is associated with diseases, including cancer, diabetes, obesity, and developmental and neurological disorders ([@r35]; [@r46]). DNA methylation marks at imprinted DMRs are generally maintained in tissues from the three germ layers ([@r45]; [@r66]; [@r69]). Furthermore, with imprinted genes often occurring in clusters ([@r22]) and with the potential for network regulation ([@r63]), the methylation status of a single DMR could affect the expression of multiple genes.

The availability of childhood blood lead concentration data and adult peripheral blood DNA from the Cincinnati Lead Study cohort ([@r9]; [@r18], [@r17], [@r19]) provided the impetus for the first determination of prenatal and postnatal lead exposure associations with DNA methylation in adulthood for the DMRs of 22 imprinted genes, as recently described ([@r57]).

Materials and Methods
=====================

*Study population*. Participants comprised 41 men and 64 women born between 1979 and 1984 who were enrolled in the Cincinnati Lead Study and were successfully recontacted in 2008--2010. Accrual and lead measurement methods have been described in detail ([@r9]; [@r18]). Briefly, pregnant women living in neighborhoods with high prevalence of pediatric lead poisoning were eligible. Women with type 1 or type 2 diabetes and neurological, psychiatric, or drug addiction disorders were excluded, as were offspring with defects or birth weight \< 1,500 g. Using anodic stripping voltammetry ([@r55]), lead concentrations were measured in first- and second-trimester maternal peripheral blood and in blood collected from their children at 10 days of age, every 3 months for the first 60 months, and every 6 months from 60 to 78 months. Umbilical cord blood was not measured due to clotting. During pregnancy, questionnaires were used to collect data on maternal race/ethnicity (black/white), the number of cigarettes smoked per day, education, occupation, continuous IQ, use of alcohol (yes/no), marijuana (yes/no), and narcotics (yes/no), and children's IQ at age 6.5 years. The protocol was approved by review boards for Cincinnati, Duke, and North Carolina State Universities.

*Specimen handling.* During the 2008 visit, 108 participants with an average age of 27 years (25--30 years) provided informed consent before peripheral blood specimens for DNA methylation analysis were collected; 105 also had covariable data. Blood was collected in K~2~EDTA-treated vaccutainer tubes, centrifuged for plasma and buffy coat isolation, and shipped to the Jirtle laboratory at Duke University for DNA methylation analysis.

*Quantitative methylation analysis.* DNA was extracted using Puregene reagents according to manufacturer's protocol (Qiagen, Valencia, CA). In the Supplemental Material, Table S1 summarizes DMR amplicon cleavage fragments, including CpG content and positions. DNA amplification used a touchdown polymerase chain reaction (PCR) protocol.

Quantitative DNA methylation analysis was performed in two batches using the Sequenom MassARRAY EpiTYPER (Sequenom, San Diego, CA). Primers for human imprinted genes were designed with the use of Epidesigner software (Sequenom) to amplify approximately 400--600 bp of the imprinted gene DMRs. Cycling conditions for touchdown PCR used are in Supplemental Material, Table S2, and primers and amplicon data are provided in Supplemental Material, Table S3. Genomic DNA (2 μg) was treated with sodium bisulfite using the EpiTect kit, according to manufacturer's protocols (Qiagen, Valencia, CA). Bisulfite-converted DNA (50 ng) was amplified by PCR using HotStarTaq (Qiagen).

PCR products were processed by dephosphorylation of unincorporated dNTPs. They were then transcribed *in vitro* with concurrent RNase cleavage using T-cleavage assays according to the manufacturer's standard protocol (Sequenom). The transcription reaction was conditioned to remove cations by adding 20 μL H~2~O and 6 mg of Clean Resin (Sequenom). Subsequently, the samples were spotted on a 384-pad Spectro-CHIP (Sequenom), using a MassARRAY Nanodispenser (Samsung, Irvine, CA), followed by spectral acquisition on a MassARRAY analyzer compact MALDI-TOF MS (matrix-assisted laser desorption/ionization time-of-flight mass spectrometer) (Sequenom). The percent methylation of CpG sites for each cleavage fragment was determined using EpiTyper software (Sequenom).

The Sequenom MassARRAY measured DNA methylation using fragments of reverse-transcribed PCR products, and data output is in CpG "units" in which multiple CpG sites may reside within a single fragment produced by RNase cleavage of transcripts of DMR amplicons (see Supplemental Material, Table S1). The mass difference between fragments with "T" and "C" bases (bisulfite-converted unmethylated, and unconverted methylated cytosines, respectively) at CpG sites was detected, and the ratio of alternate masses was quantitated to generate the methylation fraction. For fragments with multiple CpGs, the methylation value was calculated as an average of all sites. Visual inspection of the output from the mass spectrometer for such fragments with multiple CpGs provided an estimate of the accuracy of this average for individual sites. The detection of primarily two peaks representing hypomethylated and hypermethylated fragments was indicative of strand-specific, *cis*-regulated differential methylation, and the methylation value for the entire fragment was considered to represent each individual CpG site. For most fragments with multiple CpG sites, this two-peak output was the case.

In the Supplemental Material, Table S1 summarizes fragments for each amplicon, CpG content, and position within the fragments and shows which fragments were excluded from analysis due to low or high mass outside the detection range, fragment duplication, overlap, or success rate below the 95% threshold. Methylation values for fragments with multiple CpG sites were weighted when included in DMR average methylation, and fragments with duplicate masses were included separately, such that the DMR average methylation is the same as if data for each CpG were available.

Reproducibility of 5--10% for MassARRAY methylation analysis was verified in triplicate for the 22 DMRs using control conceptus tissues representing the three germ layers. In these control fetal tissues, the mean DNA methylation ranged from 45% to 60%. In humans exposed to varying lead levels, the mean DNA methylation ranged from 37% to 74% (see Supplemental Material, Table S3). When \> 5% of samples produced no signals, indicating errors in spotting or failures in amplification or cleavage, the run was discarded.

*Statistical analyses, DNA methylation, and covariable data.* A total of 172 CpG-containing cleavage fragments from 22 genomically imprinted gene DMRs had methylation percentages available for the 105 participants. The number of analyzed regions for each DMR and the mean methylation for each DMR computed from nonmissing CpG-containing fragments are in the last two columns of Supplemental Material, Table S3. The R-package was used for data analysis ([@r51]).

Lead concentrations (micrograms per deciliter) were analyzed as age-specific concentrations cumulatively defined as the sum of blood lead measurements up to and including the value measured at that age, divided by the number summed (e.g., concentrations at 10 days + 3 months + 6 months/3 = average cumulative concentrations at age 6 months). Lead values were also arrayed and the maximum lead value for each participant was identified. Lead was also categorized into four developmental stages at measurement: prenatal (first- or second-trimester gestation); neonatal (age 10 days); early childhood, coinciding with higher concentrations characteristic of the crawling/oral exploratory developmental window (age 3--30 months); and middle childhood, coinciding with declining concentrations (age 33--78 months). Factors shown to be associated with lead concentrations, from previous analyses of these data ([@r9]; [@r18]), and factors known to be associated with DNA methylation were evaluated for confounding in the overall mean and maximum saturated models. Only those with a *p*-value \< 0.05 were retained in refined models. Factors evaluated for confounding were maternal education, smoking, and race, as well as offspring sex and batch. Only sex (male/female), batch (first or second), and smoking (none, ≤ 0.5, 1, 1.5, and 2 packs per day, computed from the number of cigarettes smoked daily, assuming 20 cigarettes in a pack) remained significant, and were retained in refined models.

Because some DNA methylation values were not normally distributed, the log~2~ of the standardized regression coefficients,
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were used in adjusted linear regression models. These were compared with unstandardized regression coefficients, and the results were similar (data not shown). For ease of interpretation, we present unstandardized regression coefficients with 95% confidence intervals (CIs) in tables, whereas regression coefficients at each lead measurement are plotted without confidence intervals. A *p*-value ≤ 0.05 was considered statistically significant.

The limited sample size precluded adjustment for multiple comparisons. Instead, we included only DMRs for which the level of methylation of more than three CpG-containing fragments were correlated *r* \> 0.8, suggesting *cis*-acting regulation (data not shown). The CpG-containing fragments also had to have persistent significant (*p* \< 0.05) associations with lead exposure for any four consecutive mean lead measurements (e.g., associations were significant and in the same direction for lead levels measured at 3, 6, 9, and 12 months) as seen in [Figure 1](#f1){ref-type="fig"}.

![Number of consecutive ages of measurement with significant (*p* ≤ 0.05) association of DMR methylation with lead exposure from birth to age 78 months. The dashed line indicates the threshold for imprinted gene inclusion.](ehp.1408577.g001){#f1}

Results
=======

*Study participants, lead concentrations, and DNA methylation.* The majority (90%) of participants were born to black women, \~ 70% had less than a high school education, and the median IQ was 75 ([Table 1](#t1){ref-type="table"}). Although \~ 50% of participants were exposed to cigarette smoke *in utero*, exposure to alcohol, marijuana, and narcotics was uncommon (\< 13%). Prenatal mean (± SD) blood lead concentration was 9.1 ± 6.0 μg/dL, postnatal mean lead concentration was 13.6 ± 5.5 μg/dL, and the maximum mean was 25.3 ± 5.3 μg/dL. Blood lead concentrations in males and females were comparable throughout the study visits; the concentration increased rapidly with age, peaking at age 20--25 months, and then decreased ([Figure 2](#f2){ref-type="fig"}). Lead concentrations and the distribution of covariable data were comparable with those who were successfully contacted again in 2008--2010 (*p* ≥ 0.14).

###### 

Characteristics of study participants \[*n* (%)\].

  Characteristic                                                                    Total sample           Males (*n*=41)         Females (*n*=64)
  --------------------------------------------------------------------------------- ---------------------- ---------------------- ----------------------
  Race                                                                                                                            
  White                                                                             10 (9.5)               5 (12.2)               5 (7.8)
  Black                                                                             95 (90.5)              36 (87.8)              59 (92.2)
  Education                                                                                                                       
  ≤High school                                                                      71 (67.7)              33 (80.5)              38 (59.3)
  \>High school                                                                     34 (32.4)              8 (19.5)               26 (40.6)
  Range (years)                                                                     6--16                  9--16                  6--16
  Maternal alcohol use                                                                                                            
  Yes                                                                               13 (12.4)              4 (9.8)                9 (14.1)
  No                                                                                92 (87.6)              37 (90.2)              55 (85.9)
  Maternal narcotic use                                                                                                           
  Yes                                                                               1 (1.5)                0 (0.0)                1 (1.6)
  No                                                                                104 (98.5)             40 (100.0)             63 (98.4)
  Maternal marijuana use                                                                                                          
  Yes                                                                               11 (10.5)              4 (9.8)                7 (10.9)
  No                                                                                94 (89.5)              37 (90.2)              57 (89.1)
  Maternal tobacco use during pregnancy^*a*^                                                                                      
  None                                                                              48 (45.7)              23 (56.1)              25 (39.1)
  \<pack/day                                                                        43 (41.0)              13 (31.7)              30 (40.6)
  1 pack/day                                                                        11 (10.5)              3 (7.2)                8 (12.5)
  1.5 packs/day                                                                     2 (1.9)                1 (2.4)                1 (1.6)
  2 packs/day                                                                       1 (1.0)                1 (2.4)                0 (0)
  Birth weight (g) \[median (range)\]                                               3,096 (1,990--4,340)   3,184 (2,000--4,260)   3,040 (1,990--4,340)
  Maternal IQ \[median (range)\]                                                    75 (58--102)           74 (61--97)            76 (58--102)
  Participant IQ \[median (range)\]                                                 87 (50--116)           87 (50--111)           88 (67--116)
  Lead concentrations during developmental windows (μg/L)                                                                         
  Childhood (birth to 78months) (mean)                                              13.6 (5.5)             13.7 (5.5)             13.5 (5.5)
  Neonatal period (≤28 days)                                                        14.5 (5.9)             14.5 (6.1)             14.5 (5.7)
  Early childhood (age ≤30months)                                                   14.5 (5.9)             14.5 (6.1)             14.5 (5.7)
  Middle childhood (\>30--78months)                                                 13.0 (6.1)             13.2 (5.9)             12.8 (6.2)
  Age (years) at blood draw for DNA methylation determination \[median (range)\]    26.7 (25.4--29.6)      26.9 (25.5--29.6)      26.5 (25.4--28.4)
  ^***a***^Packs per day is based on a typical American package of 20 cigarettes.                                                 
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Data for 37 of 172 CpG-containing fragments were missing for \> 5% of participants, leaving 135 fragments for analysis. The mean DMR methylation levels for the 105 participants exposed to varying levels of lead ranged from 37% to 74% (see Supplemental Material, Table S3).

*Associations between early lead exposure and DMR methylation.* Lead concentrations were highly correlated within individuals, especially in early childhood (see Supplemental Material, Table S4). Of the 22 DMRs, those for six imprinted genes had more than three CpGs with correlation \> 0.8---*PEG10, DLK1/MEG3, DIRAS*, *PEG3*, *IGF2/H19,* and *PLAGL1/HYMA1.* However, the mean and maximum lead concentrations were persistently associated only with the DNA methylation of DMRs for *PEG3*, *IGF2/H19*, and *PLAGL1/HYMAI* ([Table 2](#t2){ref-type="table"} and [Figure 3](#f3){ref-type="fig"}; see also Supplemental Material, Table S5).

###### 

Regression coefficients for the association between mean lead exposure and *PEG3, IGF2/H19*, and *PLAGL1/HYMAI* DMR methylation.*^a^* ^,^ *^b^*

  DMR/CpG Lead exposure                                                                                                                                                                                                                                                                                                                                                                                                           Both sexes                             Males                                  Females
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------- -------------------------------------- ---------------------------------------
  *PEG3*                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  Mean life childhood lead levels (birth to age 78months)                                                                                                                                                                                                                                                                                                                                                                         --0.0014 (--0.0023, --0.0005), 0.002   --0.0024 (--0.0038, --0.0009), 0.003   --0.0009 (--0.0020, 0.0003), 0.1
  Prenatal lead levels (2nd or 3rd trimester)                                                                                                                                                                                                                                                                                                                                                                                     --0.0011 (--0.0028, 0.0005), 0.2       0.00001 (--0.0028, 0.0028), 1.0        --0.0017 (--0.0037, 0.0004), 0.1
  Neonatal lead levels (age 10 days)                                                                                                                                                                                                                                                                                                                                                                                              --0.0010 (--0.0025, 0.0004), 0.2       --0.0011 (--0.0030, 0.0007), 0.2       --0.0010 (--0.0035, 0.0016), 0.5
  Early childhood levels (age 3--30months)                                                                                                                                                                                                                                                                                                                                                                                        --0.0012 (--0.0020, --0.0004), 0.005   --0.0023 (--0.0036, --0.0009), 0.002   --0.0006 (--0.0016, 0.0005), 0.3
  Middle childhood levels (age 33--78months)                                                                                                                                                                                                                                                                                                                                                                                      --0.0013 (--0.0021, --0.0005), 0.002   --0.0018 (--0.0031, --0.0004), 0.02    --0.0009 (--0.0020, 0.0001), 0.1
  *IGF2/H19*                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  Mean life childhood lead levels (birth to age 78months)                                                                                                                                                                                                                                                                                                                                                                         --0.0013 (--0.0023, --0.0003), 0.01    --0.0004 (--0.0023, 0.0015), 0.7       --0.0017 (--0.0029, --0.0006), 0.005
  Prenatal lead levels (2nd or 3rd trimester)                                                                                                                                                                                                                                                                                                                                                                                     --0.0004 (--0.0022, 0.0014), 0.7       0.0007 (--0.0025, 0.0040), 0.7         --0.0011 (--0.0033, 0.0011), 0.3
  Neonatal lead levels (age 10 days)                                                                                                                                                                                                                                                                                                                                                                                              --0.0013 (--0.0029, 0.0003), 0.1       --0.0009 (--0.0032, 0.0013), 0.4       --0.0025 (--0.0052, 0.0002), 0.08
  Early childhood levels (age 3--30months)                                                                                                                                                                                                                                                                                                                                                                                        --0.0009 (--0.0019, 0.00001), 0.06     0.0004 (--0.0014, 0.0022), 0.7         --0.0016 (--0.0027, --0.0005), 0.007
  Middle childhood levels (age 33--78months)                                                                                                                                                                                                                                                                                                                                                                                      --0.0013 (--0.0022, --0.0004), 0.005   --0.0009 (--0.0026, 0.0008), 0.3       --0. 0016 (--0.0027, --0.0004), 0.008
  *PLAGL1/HYMAI*                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
  Mean life childhood lead levels (birth to age 78months)                                                                                                                                                                                                                                                                                                                                                                         0.0016 (--0.0021, 0.0052), 0.4         0.0023 (--0.0046, 0.0091), 0.5         --0.0001 (--0.0045, 0.0044), 1.0
  Prenatal lead levels (2nd or 3rd trimester)                                                                                                                                                                                                                                                                                                                                                                                     --0.0023 (--0.0091, 0.0044), 0.5       --0. 0041 (--0.0160, 0.0078), 0.5      --0.0023 (--0.0104, 0.0058), 0.6
  Neonatal lead levels (age 10 days)                                                                                                                                                                                                                                                                                                                                                                                              0.0075 (0.0018, 0.0132), 0.01          0.0074 (--0.0001, 0.0150), 0.06        0.0030 (--0.0069, 0.0129), 0.6
  Early childhood levels (age 3--30months)                                                                                                                                                                                                                                                                                                                                                                                        0.0024 (--0.0011, 0.0059), 0.2         0.0055 (--0.0006, 0.0115), 0.08        0.00001 (--0.0042, 0.0042), 1.0
  Middle childhood levels (age 33--78months)                                                                                                                                                                                                                                                                                                                                                                                      0.0006 (--0.0028, 0.0040), 0.7         --0.0009 (--0.0071, 0.0053), 0.8       --0.0001 (--0.0043, 0.0042), 1.0
  ^***a***^Unstandardized regression coefficients. All models were adjusted for batch (first or second) and maternal cigarette smoking (none, one-half, 1 and 2 packs a day). Models of combined estimates for males and females are also adjusted for sex. ^***b***^Mean for each developmental period (early childhood) was derived by summing up lead levels for the participant and dividing by the number of observations.                                                                                 
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*Childhood lead levels and* PEG3 *DMR methylation*. [Table 2](#t2){ref-type="table"} shows an association between mean lead concentrations across childhood and lower *PEG3* DMR methylation in adulthood (β = --0.0014; 95% CI: --0.0023, --0.0005, *p* = 0.002). These associations were primarily in males (β = --0.0024; 95% CI: --0.0038, --0.0009, *p* = 0.003) compared with females (β = --0.0009; 95% CI: --0.0020, 0.0003, *p* = 0.1). The cross-product term *p*-value for mean lead concentrations and sex was 0.09. This association in males corresponds to a 0.24% decrease in CpG methylation at the *PEG3* DMR, for every 1-μg/dL increase in lead concentration.

There were statistically significant inverse associations between *PEG3* DMR methylation and lead levels in early (β = --0.0012; 95% CI: --0.0020, --0.0004, *p* = 0.005) and middle childhood (β = --0.0013; 95% CI: --0.0021, --0.0005, *p* = 0.002). The associations were significant only in males during early (β = --0.0023; 95% CI: --0.0036, --0.0009, *p* = 0.002 for males and β = --0.0006; 95% CI: --0.0016, 0.0005, *p* = 0.3 for females) and middle childhood (β = --0.0018; 95% CI: --0.0031, --0.0004, *p* = 0.02 for males and β = --0.0009; 95% CI: --0.0020, 0.0001, *p* = 0.1 for females). Cross-product terms for early and middle childhood lead exposure and sex were *p* = 0.04 and 0.3, respectively. There were no statistically significant associations between prenatal or neonatal lead concentration and *PEG3* DMR methylation, although the direction of associations was largely similar to those of early and middle childhood.

Patterns of association observed in overall and sex-specific mean lead concentrations were also evident when maximum lead concentrations were considered (see Supplemental Material, Table S5). The association between the maximum lead concentration and decreased *PEG*3 DMR methylation in adulthood (β = --0.0007; 95% CI: --0.0012, --0.0003, *p* = 0.003) was also more apparent in males (β = --0.0013; 95% CI: --0.0021, --0.0006, *p*-value = 0.001) than in females (β = --0.0004; 95% CI: --0.0010, 0.0002, *p* = 0.3). Maximum lead concentrations in the prenatal and neonatal ages were too low for meaningful analyses.

To refine potential windows of vulnerability, nonstandardized regression coefficients were plotted for the associations between DMR methylation and averaged cumulative lead concentrations for each age at which lead was measured ([Figure 3](#f3){ref-type="fig"}). [Figure 3A](#f3){ref-type="fig"} confirms the association in [Table 2](#t2){ref-type="table"} that higher lead exposure is associated with lower *PEG3* DMR methylation, and also shows that this association does not vary significantly after age 12--20 months to age 6.5 years, despite wide variation in lead concentrations during the observation period. These associations are male-specific.

*Childhood lead levels and* IGF2/H19 *DMR methylation.* Regression coefficients and *p-*values for the association between mean lead concentration and *IGF2/H19* DMR methylation in adulthood are also shown in [Table 2](#t2){ref-type="table"}. Mean childhood lead concentration was significantly associated with adult *IGF2/H19* DMR methylation (β = --0.0013; 95% CI: --0.0023, --0.0003, *p* = 0.01). This association may be stronger in females (β = --0.0017; 95% CI: --0.0029, --0.0006, *p* = 0.005) than in males (β = --0.0004; 95% CI: --0.0023, 0.0015, *p* = 0.7).

Associations for lead exposure and *IGF2/H19* DMR methylation were also found in early (β = --0.0016; 95% CI: --0.0027, --0.0005, *p* = 0.007) and middle childhood (β = --0.0016; 95% CI: --0.0027, --0.0004, *p* = 0.008) in females. These associations were weaker and less consistent in males, for early (β = 0.0004; 95% CI: --0.0014, 0.0022, *p* = 0.7) and middle childhood (β = --0.0009; 95% CI: --0.0026, 0.0008, *p* = 0.3). The *p*-values for cross-product terms for early and middle childhood lead levels and sex were 0.10 and 0.6, respectively. This age- and sex-specific pattern of association was also noted when maximum blood lead concentrations were evaluated (see Supplemental Material, Table S5). As with the *PEG3* DMR methylation, associations with prenatal and neonatal exposure were weaker although in the same direction.

Further exploration of cumulative lead concentrations suggests a female-specific association between lead exposure and lower methylation at the *IGF2/H19* DMR. The magnitude of the association between cumulative lead concentration and *IGF2/H19* DMR methylation was the same after 12--20 months ([Figure 3B](#f3){ref-type="fig"}). As with *PEG3* DMR, this similarity persists for the entire observation period.

*Childhood lead levels and* PLAGL1/HYMAI *DMR methylation.* Unlike *IGF2/H19* and *PEG3*, which showed no evidence for association between neonatal lead exposure and DMR methylation, *PLAGL1/HYMAI* DMR methylation was positively associated with lead levels during this period (β = 0.0075; 95% CI: 0.0018, 0.0132, *p* = 0.01). The wide confidence intervals suggest that this association varied little between males (β = 0.0074; 95% CI: --0.0001, 0.0150, *p* = 0.06) and females (β = 0.0030; 95% CI: --0.0069, 0.0129, *p* = 0.6). No significant association was found between lead exposure and *PLAGL1/HYMAI* DMR methylation at any other age. Refined age-dependent and sex-specific analyses suggest that the magnitude of associations remained unaltered after \~ 12--20 months to the end of the observation period ([Figure 3C](#f3){ref-type="fig"}).

Discussion
==========

The DMRs regulating monoallelic expression of imprinted genes are proposed to function as epigenetic archives of early exposure to environmental factors ([@r33]). Nevertheless, until now, no empirical data have demonstrated associations between early exposure to lead and adult CpG methylation at DMRs controlling the parent-of-origin silencing of imprinted genes. Environmentally induced DNA methylation changes at imprint DMRs are usually stable once established ([@r31]), and have been associated with common chronic diseases and conditions, including neurological disorders, obesity, type 2 diabetes, and some cancers ([@r2]; [@r26]; [@r32]; [@r35]).

We have undertaken an analysis of 22 DMRs regulating human imprinted genes, and evaluated relationships between DNA methylation in adulthood and lead exposure spanning from the first or early second trimester to age 6.5 years. Our key findings were that childhood lead exposure was associated with significantly lower DNA methylation levels at the DMR regulating *PEG3*. We also found modest but consistent associations between average lead concentration and decreased methylation of the *IGF2/H19* DMR, and higher DNA methylation levels at the *PLAGL1/HYMAI* DMR in relation to neonatal exposure. These data further indicated that although childhood lead exposure was associated with differences in *PEG3* DMR methylation in males and the *IGF2/H19* DMR methylation in females, the association between neonatal lead concentrations and *PLAGL1/HYMAI* DMR methylation may not be sex-specific. Notably, lead associations with DNA methylation of imprint regulatory elements at these three loci were found in lead measured before age 30 months, regardless of sex or DMR. These data support the contention that environmentally driven perturbations at these DMRs occur early. Furthermore, developmental differences between the sexes may dictate the patterns of gene regulation that ensue in response to early challenges with this heavy metal.

PEG3 *DMR methylation and early lead exposure.* Although childhood lead exposure has been associated with increased risk of neurodevelopmental disorders ([@r16]), the mechanisms underlying these pathological conditions are poorly understood. *PEG3* plays a critical role in brain development, with expression mainly in the mesencephalon and pituitary gland; in the adult brain *PEG3* is found primarily in the hypothalamus and the pituitary gland ([@r39]). In mouse models, *Peg3* also plays an important role in social and maternal nurturing behaviors, and paternal transmission of disrupted *Peg3* also leads to restricted growth ([@r11]; [@r39]). In humans, hypermethylation at this locus has been associated with decreased gene expression of this tumor suppressor gene in cervical ([@r48]) and ovarian ([@r27]) cancers. In primary neuronal cell cultures derived from wild-type, p53-deficient, or Bax-deficient mice, overexpression of *Peg3* led to decreased neuronal viability via *p53* and *Bax* dependent pathways ([@r36]). It is therefore possible that the male-specific reduced brain volume recently observed in these study participants ([@r9]) may result, in part, from the dysregulation of *PEG3* during early development.

Interestingly, early-childhood but not prenatal or neonatal lead levels were associated with adulthood *PEG3* DMR hypomethylation, an association that may be specific to males. Because these DNA methylation marks are established early, it is possible that methylation differences observed were attributable to lead accumulated *in utero* and mobilized from soft tissue and bone after birth together with concurrent exposure. Alternatively, the reduced DNA methylation of the *PEG3* DMR marks may have been established postnatally ([@r40]). The latter possibility is consistent with human developmental studies suggesting that the first 1,000 days can dictate lifetime risk of common diseases ([@r64]). Discriminating between these possibilities requires larger studies with long-term follow-up.

IGF2/H19 *imprinted domain and early lead exposure.* The paternally expressed *insulin-like growth factor-2* (*IGF2*) is a commonly studied imprinted gene, and is frequently shown to be altered epigenetically by *in utero* environmental perturbations, and in cancer ([@r12], [@r13]; [@r14]; [@r31]; [@r34], [@r32]; [@r44]). Dysregulation of the *IGF2/H19* domain was initially associated with Beckwith--Wiedemann syndrome (BWS) ([@r24]). Decreased DNA methylation at the *IGF2/H19* DMR has been associated with reduced *IGF2* expression in bladder cancer ([@r61]). This occurs when enhanced binding of the CTCF insulator protein to the normally unbound paternal allele ([@r47]) blocks promoter interactions with downstream enhancers, thereby reducing gene expression ([@r30]; [@r37]). *Igf2* over-expression results in animal overgrowth ([@r58]), whereas gene repression results in restricted growth ([@r15]). IGF2 is also required for memory formation ([@r10]).

PLAGL1/HYMA1 *imprinted domain and early lead exposure.* A higher-order regulation of imprinted gene clusters is thought to exist and occur through epigenetic marks present at imprinting centers ([@r38]). Our finding that neonatal lead exposure is associated with increased methylation at the *PLAGL1/HYMAI (ZAC)* DMR regardless of sex is potentially of biological importance. In animals, microarray analysis shows that knockout of the mouse homolog, *Zac1 (Plagl1),* disrupts a network of coordinately regulated genes containing a large number that are also imprinted ([@r63]). *In vitro* studies show induction of imprinted *Igf2*, *Cdkn1c, H19, Dlk1*, and *Mest* when *Zac1* is overexpressed ([@r63]). Conversely, loss of *Zac1* expression in null mice results in inhibition of *Igf2, Cdkn1c, H19*, and *Dlk1* expression. Another imprinted gene network was identified by analyzing chromatin domains in other regions of the genome that interact with the *Igf2/H19* domain, *in vitro* ([@r73]). The maternally expressed long noncoding *H19* RNA and the methyl-CpG--binding protein Mbd1 form a complex that regulates multiple imprinted genes by interacting with histone lysine methyltransferases. In mice, paternally expressed *Plagl1* is implicated in transient neonatal diabetes when overexpressed ([@r43]). In ovarian cell lines, *PLAGL1* was found to regulate *CDKN1C (p57^KIP2^)* expression and cell growth by inducing *LIT1* transcription in a methylation-dependent manner ([@r1]). Overexpression of *PLAGL1* induced *IGF2, H19*, and *CDKN1C* expression in a prostate cancer cell line ([@r54]). Together, these studies support a set of imprinted genes functioning in a network, coordinated in part by *Zac* ([@r29]; [@r41]). Thus, environmentally induced epigenetic shifts of the *PLAGL1/HYMAI* regulatory DMR have the potential to alter network-wide imprinted gene expression. Studies with a larger number of DMRs are required to clarify the role of the *PLAGL1/HYMAI* DMR in the higher-order regulation of imprint clusters. Nevertheless, our findings are consistent with the idea that the far-reaching effects of early lead exposure may be mediated by stable, mitotically heritable epigenetic alterations in DMRs controlling imprinted gene expression.

A cautious interpretation of our findings is warranted. Although lead is known to target multiple organs, DNA methylation was measured using unfractionated peripheral blood collected in adulthood---the only accessible cell type---raising concerns about potential confounding by cell type, and other exposures during the life course that could not be evaluated. Another limitation of this study is the relatively small sample size, which reduced the precision of associations found. Assay limitations also precluded the measurement of DNA methylation for \~ 50% of CpGs within CpG-containing fragments. Because methylation values for CpG-containing fragments were averaged from individual CpG sites with similar methylation values and are *cis*-acting, such missing data should not alter our findings. The small amount of peripheral blood leukocyte DNA available for methylation analysis also precluded the determination of altered gene expression via other epigenetic mechanisms (e.g., histone modifications and chromatin structure changes); however, similar methylation changes at both the *IGF2/H19* and *PEG3* DMRs have been associated previously with altered gene expression in human cancers ([@r14]; [@r48]). Thus, our findings add preliminary support to accumulating evidence indicating that early lead exposure and gene-specific, epigenetic dysregulation of some imprinted gene DMRs may contribute to developmental abnormalities ([@r35]).

Our study also has major strengths. They include the determination of lead levels \~ 30 years before quantification of DNA methylation levels at imprinted gene DMRs. The numerous measurements of lead concentration during early development also facilitate estimating developmental windows in which lead exposure may exert its effects on regulatory DMRs. Furthermore, blood lead concentrations reflect both short- and longer-term exposure, including lead mobilized from physiological deposits.

To our knowledge, our findings represent the first attempt in humans to quantify associations between early lead exposure and DNA methylation alterations in adulthood at imprinted loci that are known experimentally to result in developmental and neurological disorders if perturbed early in development. Because lead exposure disproportionately affects those in the lower socioeconomic strata ([@r23]; [@r50]; [@r70]), our findings, if replicated in larger studies, may offer a potential explanation for observed DNA methylation differences among socioeconomic strata ([@r59], [@r60]).

Conclusions
===========

Preventing lead exposure during vulnerable developmental windows remains sound policy. Nevertheless, effective therapeutic and public health strategies will depend on a better understanding of mechanisms underpinning the associations between lead exposure and the genesis of neurodevelopmental disorders and other poor health outcomes. Improved understanding should also guide policy regarding the highest tolerable limits in humans, a value currently unknown. Although the small sample size limits inference, this study provides preliminary evidence for significant associations between early lead exposure and DNA methylation at the regulatory regions of *PEG3, H19/IGF2*, and *PLAGL1/HYMAI*. Because these changes in the epigenome are acquired early, resultant shifts in the regulation of imprinted genes may contribute to increased risk of poor health outcomes ([@r35]; [@r46]). It remains unknown whether lead exposure previously associated with decreased gray matter volume ([@r9]) and delinquent behavior ([@r19]) reported in this study population is mediated in part by the epigenetic alterations in imprinted gene regulatory elements, but this intriguing possibility needs to be investigated.
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=====================
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